Accumulation of gold nano-rods in the failing heart of transgenic mice with the cardiac-specific expression of TNF-α.
Gold nano-rod
Heart failure
Inflammation
TNF-α
Journal
Heart and vessels
ISSN: 1615-2573
Titre abrégé: Heart Vessels
Pays: Japan
ID NLM: 8511258
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
05
03
2018
accepted:
17
08
2018
pubmed:
31
8
2018
medline:
19
3
2019
entrez:
31
8
2018
Statut:
ppublish
Résumé
Gold nano-rods, rod-shaped gold nanoparticles, act as contrast agents for in vivo bioimaging, drug delivery vehicles and thermal converters for photothermal therapy. Pro-inflammatory cytokines play critical roles in the development of heart failure. We examined the delivery of GNRs into the failing heart of a transgenic (TG) mouse model of inflammatory cardiomyopathy with the cardiac-specific overexpression of TNF-α. We modified GNRs with polyethylene glycol (PEG) to avoid cytotoxicity and reduce the rapid clearance of nanoparticles from blood. PEG-modified GNRs (4.5 mM as gold atoms, 200 μL) were administered intravenously to TG (n = 7) and wild-type (WT) mice (n = 5). These were killed 24 h later, and the heart, lung, liver, kidney and spleen were excised. A quantitative analysis of gold was performed using inductively coupled plasma mass or optical emission spectrometry. The amount of gold (ng) in the TG heart (3.24 ± 1.56 ng/mg heart weight) was significantly greater than that in the WT heart (1.01 ± 0.19; p < 0.05). No significant differences were observed among the other organs of TG and WT mice. The amount of gold in the TG heart was significantly and positively correlated with the ratio of the ventricular weight to body weight, which is known to be an index of ventricular hypertrophy. In conclusion, PEG-modified GNRs accumulated in the inflammatory TG heart in proportion with the severity of ventricular hypertrophy.
Identifiants
pubmed: 30159657
doi: 10.1007/s00380-018-1241-2
pii: 10.1007/s00380-018-1241-2
doi:
Substances chimiques
Tumor Necrosis Factor-alpha
0
Gold
7440-57-5
DNA
9007-49-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
538-544Références
J Am Coll Cardiol. 2000 Mar 1;35(3):537-44
pubmed: 10716453
J Clin Invest. 2000 Aug;106(4):589-97
pubmed: 10953034
Circ Res. 2002 Nov 29;91(11):988-98
pubmed: 12456484
Circulation. 2004 Apr 20;109(15):1892-7
pubmed: 15051641
Dev Dyn. 2005 Jan;232(1):67-74
pubmed: 15580571
Eur Heart J. 2005 Jan;26(1):65-9
pubmed: 15615801
Chem Commun (Camb). 2005 May 7;(17):2247-9
pubmed: 15856111
Am J Physiol Heart Circ Physiol. 2006 Feb;290(2):H590-8
pubmed: 16199483
Langmuir. 2006 Jan 3;22(1):2-5
pubmed: 16378388
J Control Release. 2006 Sep 12;114(3):343-7
pubmed: 16876898
Cancer Lett. 2008 Sep 28;269(1):57-66
pubmed: 18541363
Small. 2008 Jul;4(7):1001-7
pubmed: 18581412
Cancer Res. 2009 May 1;69(9):3892-900
pubmed: 19366797
J Biomater Sci Polym Ed. 2009;20(9):1203-15
pubmed: 19520008
J Control Release. 2009 Oct 1;139(1):81-4
pubmed: 19538994
ACS Nano. 2011 Feb 22;5(2):1086-94
pubmed: 21244012
ACS Nano. 2011 Nov 22;5(11):8967-73
pubmed: 22003968
Am J Physiol Heart Circ Physiol. 2012 Jun 1;302(11):H2352-62
pubmed: 22492716
Nanoscale Res Lett. 2012 Oct 11;7(1):565
pubmed: 23050635
Eur J Heart Fail. 2016 Feb;18(2):169-78
pubmed: 26749465
Sci Rep. 2016 Feb 01;6:20203
pubmed: 26830764
PLoS One. 2016 Aug 08;11(8):e0160944
pubmed: 27501378
Chem Pharm Bull (Tokyo). 2017;65(7):625-628
pubmed: 28674334
J Card Fail. 1997 Jun;3(2):117-24
pubmed: 9220311
Circ Res. 1997 Oct;81(4):627-35
pubmed: 9314845